clinical trial · NCT06831734
Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo
Novo Nordisk A/S·—·enrolling by invitation·n = 30
Haemophilia A, Haemophilia BConcizumab
brief summary
The purpose of the study is to investigate the safety and effectiveness of Alhemo in participants under real-world clinical practice in Japan. Total duration of this study is about 6 years. Participants enrolment will be completed in the first 4 years. The observation period of this study will last for about 2 years for each enrolled participant.
started
May 2, 2025
primary completion
Jan 31, 2031
completion
Jan 31, 2031
last updated
Aug 29, 2025
official title
Special Use-results Surveillance on Use of Alhemo in Patients With Haemophilia A or Haemophilia B Without Inhibitors A Multi-centre, Open-label, Non-interventional Post-marketing Study to Investigate the Long-term Safety and Clinical Parameters of Treatment With Alhemo in Patients With Haemophilia A or Haemophilia B Without Inhibitors in Routine Clinical Practice Conditions in Japan
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol